Mirum Pharmaceuticals
Présence
Mirum Pharmaceuticals fait partie des...
Mirum Pharmaceuticals est une société cotée sous le symbole boursier MIRM (US).
Dirigeants
Voir l'organigramme avec ses 20 principaux dirigeants
Biographies les plus recherchées chez Mirum Pharmaceuticals
- Chris Peetz, Director, President and Chief Executive Officer
- Mike Grey, Executive Chairman of the Board
- William Fairey, Director
Changements de dirigeants chez Mirum Pharmaceuticals
- Joanne Quan, a rejoint l'entreprise comme Chief Medical Officer (publié le 17 janvier 2024).
- Eric Bjerkholt, a rejoint l'entreprise comme Chief Financial Officer (publié le 12 septembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Mirum Pharmaceuticals.
Pharmacie
Mirum Pharmaceuticals a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Mirum Pharmaceuticals
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Mirum Pharmaceuticals
- Mirum Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Mirum Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Chris Peetz 
Appelez Mirum Pharmaceuticals au +1 650...
